SCHEMBL15499882

SCHEMBL15499882

CCOC(=O)c1nc(C2CCCCCCCCCCCCC2)cs1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.49
RORC P51449 1/20 0.42
TMIGD3 P0DMS9 1/20 0.41
ADORA1 P30542 1/20 0.41
ALDH1A1 P00352 5/20 0.40
HPGD P15428 3/20 0.40
MAPT P10636 2/20 0.40
MEN1 O00255 1/20 0.40
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
KMT2A Q03164 1/20 0.40
KDM4E B2RXH2 1/20 0.40
CTSK P43235 1/20 0.40
CSNK1D P48730 1/20 0.40
ALOX15 P16050 1/20 0.39
HSD17B10 Q99714 1/20 0.39
NR1H4 Q96RI1 1/20 0.39
GAA P10253 1/20 0.39
LMNA P02545 1/20 0.38
TDP1 Q9NUW8 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18811612 1.00 SMN1; SMN2 (0.49) SMN1; SMN2RORCTMIGD3ADORA1ALDH1A1
SCHEMBL9261452 1.00 SMN1; SMN2 (0.49) SMN1; SMN2RORCTMIGD3ADORA1ALDH1A1
SCHEMBL21510767 0.99 SMN1; SMN2 (0.47) SMN1; SMN2RORCTMIGD3ADORA1ALDH1A1
SCHEMBL9094106 0.96 SMN1; SMN2 (0.44) SMN1; SMN2RORCTMIGD3ADORA1ALDH1A1
SCHEMBL577947 0.93 TMIGD3 (0.47) SMN1; SMN2TMIGD3ADORA1ALDH1A1HPGD
SCHEMBL21063663 0.83 MAPT (0.40) SMN1; SMN2ALDH1A1MAPTMEN1NPC1
SCHEMBL16445934 0.80 CDK5 (0.39) SMN1; SMN2TMIGD3ADORA1ALDH1A1MAPT
SCHEMBL15537682 0.78 SMN1; SMN2 (0.47) SMN1; SMN2ALDH1A1HPGDMAPTMEN1
SCHEMBL15551276 0.78 SMN1; SMN2 (0.47) SMN1; SMN2ALDH1A1HPGDMAPTMEN1
SCHEMBL17709829 0.77 SMN1; SMN2 (0.45) SMN1; SMN2ALDH1A1HPGDMAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9018380-B2 Heterocyclic modulators of HIF activity for treatment of disease Boar of Regents, The University of Texas System (US) 2015-04-28 US disclosed
US-20140066424-A1 HETEROCYCLIC MODULATORS OF HIF ACTIVITY FOR TREATMENT OF DISEASE Institute For Applied Cancer Science/The University of Texas MD Anderson Cancer Center (US) 2014-03-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140066424-A1 HETEROCYCLIC MODULATORS OF HIF ACTIVITY FOR TREATMENT OF DISEASE HIF1AN, HIF1A, EGLN3 SMN1; SMN2 4052/4885RORC 1343/4885TMIGD3 3847/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.